Healthcare 

Guggenheim Securities continues to provide healthcare clients with independent insight and expertise across the biopharma, medical devices, and healthcare services sectors. Our full-service firm includes a leading healthcare investment banking franchise, trusted as a long-term, strategic advisor, as well as capital markets solutions and a research department that performs deep primary research and generates actionable ideas.

Video Highlights

Opportunities in Healthcare Technology for Private Equity

Senior Managing Director David Blais, Healthcare Services Investment Banking, interviews Senior Managing Director Jon Pritti, Private Equity Advisory Group, to discuss the dynamics behind and opportunities around private equity’s focus on healthcare technology.
The Century Project: Living a Longer and Healthier Life

The Century Project: Living a Longer and Healthier Life

Healthcare Equities Sales Specialist Whitney Wolfe interviews Head of Equities Stefano Natella to discuss insights and highlights from 'The Century Project,' a series of reports that analyzes health factors influencing longevity and healthspan.

Watch video

Focus on M&A in Healthcare

Focus on M&A in Healthcare

Healthcare Equities Sales Specialist Whitney Wolfe interviews Senior Managing Director of Healthcare Investment Banking Punit Mehta to discuss his outlook for M&A across the healthcare industry.

Watch video

Representative Transactions in Healthcare

Joint Bookrunner to Vaxcyte.
Financial Advisor to Rite Aid.
Joint Active Bookrunner to BrightSpring Health Services.
Financial Advisor to Guidehouse.
Exclusive Financial Advisor to Ensemble Health Partners.
Financial Advisor to Revolution Medicines.
Financial Advisor to CorEvitas.
Financial Advisor to Amedisys.
Joint Active Bookrunner to MoonLake Immunotherapeutics.
Financial Advisor to Lannett Company, Inc..
Exclusive Financial Advisor to Zoetis, Inc..
Financial Advisor to Pfizer.
Financial Advisor to Summit Health-CityMD.
Financial Advisor to Select Rehabilitation.
Financial Advisor to Pfizer Inc..
Financial Advisor to Coronis Health.
Financial Advisor to Linden Capital Partners.
Strategic & Financial Advisor to Ensemble Health Partners.
Financial Advisor to Arena Pharmaceuticals.
Advised Physician Partners.
Financial Advisor to Carlyle.
Financial Advisor to Medical Properties Trust.
Financial Advisor to Myriad Genetics.
Lead Financial Advisor to Jazz Pharmaceuticals.
Financial Advisor to STERIS.
Financial Advisor to Magellan Health.
Financial Advisor to Biogen.
Financial Advisor to MyoKardia.
Financial Advisor to Paragon Healthcare.
Lead Financial Advisor to Wright Medical.
Financial Advisor to Vertiflex.
Financial Advisor to Cartiva.
Sole Financial Advisor to Stryker.
Financial Advisor to Kindred Healthcare, Inc..
Sole Financial Advisor to Teleflex.
Financial Advisor to Zeltiq.
Financial Advisor to Vascular Solutions, Inc..
Sole Financial Advisor to St. Jude Medical.
Lead Financial Advisor to Thoratec Corporation.

Social Media

Michael Schmidt's Research Featured In Barron's Article

LinkedIn: Barron's

Michael Schmidt's Research Featured In Barron's Article

Biotechnology Equity Research Analyst Michael Schmidt's research was featured in a Barron's article focusing on the recent spate of publicly announced biotech M&A transactions. The article highlighted names of oncology-focused companies that could be potential M&A targets in 2024.

Read More

Guggenheim Thanks Participants and Attendees of INI Conference

LinkedIn: INI Conference

Guggenheim Thanks Participants and Attendees of INI Conference

Guggenheim Securities, LLC would like to thank the participants and attendees of the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference, hosted by the firm's healthcare equity research analysts.

Read more

The Century Project: Living a Longer and Healthier Life

LinkedIn

The Century Project: Living a Longer and Healthier Life

Healthcare Equities Sales Specialist Whitney Wolfe interviews Head of Equities Stefano Natella to discuss insights and highlights from “The Century Project,” a series of reports that analyzes health factors influencing longevity and healthspan.

Watch video

Punit Mehta Joins CNBC's 'Squawk on the Street'

LinkedIn: CNBC

Punit Mehta Joins CNBC's 'Squawk on the Street'

Senior Managing Director Punit Mehta joins CNBC's "Squawk on the Street" to discuss his outlook for healthcare M&A.

Watch video

Whitney Wolfe and Punit Mehta Discusses Healthcare M&A Outlook

LinkedIn

Whitney Wolfe and Punit Mehta Discusses Healthcare M&A Outlook

Healthcare Equity Sales Specialist Whitney Wolfe interviews Senior Managing Director Punit Mehta, Healthcare Investment Banking, to discuss his outlook for M&A across the healthcare industry.

Watch video

Guggenheim Congratulates Relievant Medsystems, Inc. on its Transaction

LinkedIn: Relievant Medsystems

Guggenheim Congratulates Relievant Medsystems, Inc. on its Transaction

Guggenheim Securities, LLC congratulates Relievant Medsystems, Inc. in connection with its $850 million (plus additional contingent payments) sale to Boston Scientific. Guggenheim served as the exclusive financial advisor to Relievant.

Read more

Vamil Divan Speaks With Wall Street Journal

LinkedIn: WSJ

Vamil Divan Speaks With Wall Street Journal

Global Biopharmaceutical and Biotechnology Equity Research Analyst Vamil Divan, MD, MBA spoke with Peter Loftus of The Wall Street Journal about the effects of the recent business revamp by one of the world's largest healthcare companies.

Read more

Guggenheim Hires Ryan Lindquist to Expand Healthcare Investment Banking Practice

LinkedIn: Ryan Lindquist

Guggenheim Hires Ryan Lindquist to Expand Healthcare Investment Banking Practice

Guggenheim Securities, LLC announced today that Ryan Lindquist has joined the firm as a Senior Managing Director in its Healthcare Investment Banking practice, where he will focus on diagnostics and life science tools.

Read more

Stefano Natella and Seamus Fernandez Talk With CNBC About Sleep

LinkedIn: Sleep

Stefano Natella and Seamus Fernandez Talk With CNBC About Sleep

Head of Equities Stefano Natella and Global Biopharmaceuticals Equity Research Analyst Seamus Fernandez spoke with Michelle Fox at CNBC about the impacts of sleep deprivation and the development of sleep management drugs.

Read more

Guggenheim Congratulates Palette Life Sciences on its Sale to Teleflex

LinkedIn: Palette Life Sciences

Guggenheim Congratulates Palette Life Sciences on its Sale to Teleflex

Guggenheim Securities, LLC congratulates Palette Life Sciences in connection with its $600 million (plus up to $50 million in commercial milestones) sale to Teleflex. Guggenheim served as the exclusive financial advisor to Palette.

Read more

Guggenheim Congratulates CorEvitas, LLC, on its Transaction

LinkedIn: Corevitas

Guggenheim Congratulates CorEvitas, LLC, on its Transaction

Guggenheim Securities, LLC congratulates CorEvitas, LLC, in connection with its $912.5 million sale to Thermo Fisher Scientific. Guggenheim served as a financial advisor to CorEvitas, LLC, a portfolio company of Audax Private Equity.

Read more

Evan Wang Expands Coverage of Healthcare Stocks

LinkedIn: Evan Wang

Evan Wang Expands Coverage of Healthcare Stocks

Evan Wang, Healthcare Equity Research Analyst covering Global Biopharmaceuticals and Biotechnology, recently increased Guggenheim Securities' Healthcare Research footprint by expanding coverage in the infectious disease and liver sectors.

Read more

Guggenheim Congratulates Zoetis on its Transaction

LinkedIn: Zoetis

Guggenheim Congratulates Zoetis on its Transaction

Guggenheim Securities, LLC, congratulates Zoetis in connection with the sale of Pumpkin to JAB HOLDING COMPANY LLC.

Read more

Guggenheim Thanks Attendees and Participants of Radiopharmaceuticals Day

LinkedIn: Guggenheim Securities

Guggenheim Thanks Attendees and Participants of Radiopharmaceuticals Day

Guggenheim would like to thank the participants and attendees of the Guggenheim Healthcare Talks Radiopharmaceuticals Day.

Read more

Jennie Xue Participates in Panel at Innovation Summit Dublin

LinkedIn: #InnovationDublin23

Jennie Xue Participates in Panel at Innovation Summit Dublin

Senior Managing Director Jennie Xue, Medical Devices Investment Banking, participated in a panel at #InnovationDublin23, to provide her perspective on the current state of the medical devices M&A environment.

Read more

Guggenheim Thanks Attendees of Genomic Medicines and Rare Disease Days

LinkedIn: Rare Disease Days

Guggenheim Thanks Attendees of Genomic Medicines and Rare Disease Days

Guggenheim would like to thank the participants and attendees of the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days.

Read more

Vamil Divan Launches Healthcare Stock Coverage

LinkedIn: Healthcare Research

Vamil Divan Launches Healthcare Stock Coverage

Vamil Divan, MD, MBA, Healthcare Equity Research Analyst covering the Global Biopharmaceutical and Biotechnology sectors, expanded Guggenheim Securities’ Healthcare Research footprint in late February by launching coverage on nine healthcare stocks.

Read more

Guggenheim Thanks Attendees of Oncology Day

LinkedIn: Oncology Conference

Guggenheim Thanks Attendees of Oncology Day

Guggenheim would like to thank the participants and attendees of the Guggenheim Healthcare Talks 2023 Oncology Conference.

Read more

Guggenheim Congratulates Medusind on its Transaction

LinkedIn: Medisund

Guggenheim Congratulates Medusind on its Transaction

Guggenheim Securities, LLC congratulates Medusind, a portfolio company of H.I.G. Capital, in connection with its announced sale to Alpine Investors.

Read more

What Top Dealmakers Expect to See This Year in Health-Care M&A

LinkedIn: Bloomberg

What Top Dealmakers Expect to See This Year in Health-Care M&A

Senior Managing Directors Punit Mehta and David Blais shared their views on the M&A outlook in healthcare with Michelle Davis from Bloomberg News.

Read more

Guggenheim Congratulates Summit Health-CityMD on its Transaction

LinkedIn: Summit Health

Guggenheim Congratulates Summit Health-CityMD on its Transaction

Guggenheim Securities, LLC congratulates Summit Health-CityMD, a portfolio company of Warburg Pincus LLC, in connection with its definitive agreement to be acquired by VillageMD, an affiliate of Walgreens Boots Alliance. Guggenheim served as a financial advisor to Summit Health-CityMD on its transaction.

Read more

Seamus Fernandez Joins CNBC To Discuss Biopharmaceuticals

LinkedIn: CNBC Closing Bell: Overtime

Seamus Fernandez Joins CNBC To Discuss Biopharmaceuticals

Biopharmaceutical Analyst Seamus Fernandez provides insight on CNBC Closing Bell: Overtime into his recent report on MRK.

Watch video

Guggenheim Thanks Attendees of Immunology and Neurology Conference

LinkedIn: Immunology & Neurology Conference

Guggenheim Thanks Attendees of Immunology and Neurology Conference

Guggenheim would like to thank the presenters and attendees of the Immunology and Neurology Conference.

Read more

Guggenheim Thanks Attendees of Therapeutics Conference

LinkedIn: Therapeutics Conference

Guggenheim Thanks Attendees of Therapeutics Conference

Guggenheim would like to thank the participants and attendees of the Therapeutics Conference.

Read more

I&I Spotlight Series - Treg-based Therapies

LinkedIn: I&I Spotlight Series

I&I Spotlight Series - Treg-based Therapies

Senior Healthcare Sales Specialist Whitney Wolfe interviews Biotechnology Research Analyst Yatin Suneja on the rapid innovation of Tregs for the treatment of autoimmune diseases and diseases of the nervous system.

Read more

Guggenheim Thanks Attendees of I&I Spotlight Series

LinkedIn: I&I Spotlight Series

Guggenheim Thanks Attendees of I&I Spotlight Series

Guggenheim would like to thank the participants and attendees of the I&I Spotlight Series on Treg-based Therapies.

Read more

Guggenheim Thanks Attendees of Radiopharmaceutical Day

LinkedIn: Radiopharmaceutical Day

Guggenheim Thanks Attendees of Radiopharmaceutical Day

Guggenheim would like to thank the participants and attendees of Radiopharmaceutical Day.

Read more

Guggenheim Thanks Attendees of Synthetic Lethality Day

LinkedIn: Synthetic Lethality Day

Guggenheim Thanks Attendees of Synthetic Lethality Day

Guggenheim would like to thank the participants and attendees of Synthetic Lethality Day

Read more

Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day

LinkedIn: Genomic Medicines & Rare Disease Day

Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day

At Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day, we provided healthcare clients with access to industry leadership in the constantly evolving sector.

Read more

Highlights From the Second Guggenheim Targeted Protein Degradation Day

LinkedIn: Targeted Protein Degradation Day

Highlights From the Second Guggenheim Targeted Protein Degradation Day

Equity Research Analyst Michael Schmidt, who covers biotech, provides highlights from our Targeted Protein Degradation Day, a part of the Guggenheim Healthcare Talks series, on March 16.

Read more

Guggenheim Thanks Oncology Conference Attendees

LinkedIn: Oncology Conference

Guggenheim Thanks Oncology Conference Attendees

Guggenheim would like to thank the participants and attendees of the Oncology Conference

Read more

Guggenheim Securities Healthcare - Biopharma Perspectives

LinkedIn: Biopharma Perspectives

Guggenheim Securities Healthcare - Biopharma Perspectives

At Guggenheim Securities, LLC we provide biopharmaceutical clients with independent insight and advice. As we survey 2022, we are sharing summaries of some of our most compelling thematic reports from the past year.

Read more

To access more information related to Healthcare at Guggenheim Securities, contact GSInfo@guggenheimpartners.com.


Important Notices and Disclosures

The information and materials provided herein (the “materials”) are provided for informational and educational purposes only and should not be considered a recommendation of any particular security, strategy or investment product, as investing advice of any kind, or as offering or providing any investment product or service, or as an offer or solicitation with respect to the purchase or sale of any investment by Guggenheim Securities, LLC or any of its affiliates (“Guggenheim”). The materials are not provided in an advisory or fiduciary capacity and may not be relied upon for or in connection with the making of investment decisions. The views expressed herein are solely those of the authors and may differ from the views of other officers, directors, employees or other representatives (as to any person or entity, its “Representatives”) of Guggenheim. The authors’ opinions are subject to change without notice. Guggenheim undertakes no obligation to provide additional information or any update to or correction of the information provided herein. Sources for the information contained herein are believed to be reliable, but the information is not guaranteed as to, and Guggenheim and its Representatives make no representation or warranty regarding, accuracy or completeness of any information contained herein or otherwise. Neither Guggenheim nor its Representatives shall be liable to any person in any way whatsoever for any losses, costs or claims for reliance on the materials. Guggenheim may have a business relationship with certain issuers mentioned herein, or may otherwise underwrite, hold a position, buy or sell as principal in the securities of any issuer mentioned. Guggenheim may have in the past provided, may currently be providing and may in the future seek to provide investment banking, financial advisory and other services to, and have other material relationships with, the issuers of securities, loans and other financial instruments referred to herein and their affiliates. With respect to any position Guggenheim may hold, Guggenheim may have interests different from or adverse to your interests. None of the materials provided may be reproduced or redistributed, in whole or in part, to any other person or published in whole or in part for any purpose absent the written consent of Guggenheim. By accessing or reviewing this website, you will be deemed to have acknowledged and agreed to the matters set forth above.

Copyright © 2023 by Guggenheim Securities, LLC, a FINRA registered broker-dealer. All rights reserved.